The American Association for the Study of Liver Diseases (AASLD) has released an update of the practice guideline on the Management of Adult Patients with Ascites Due to Cirrhosis last published in 2009 in the journal HEPATOLOGY.
Cirrhosis is the eighth leading cause of death in the United
States and ascites is the most common complication of cirrhosis.
guideline is intended for physicians and allied health professionals and
provides recommendations for the diagnosis and treatment of ascites. This update
includes new sections on umbilical hernias, hepatic hydrothorax, and cellulitis.
Click here to access the updated practice guideline.
AASLD News: April 11, 2013
- Newly Diagnosed
- All FDA Approved Drugs To Treat Hepatitis C
- 2017-HCV Genotypes/Treatment
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Not FDA Approved - Sofosbuvir/Velpatasvir/Voxilaprevir
- Not FDA Approved - Glecaprevir/Pibrentasvir (G/P)
- NOT FDA Approved - MK3 (MK-3682/grazoprevir/ruzasvir1)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- Treating Elderly HCV Patients
- FibroScan® Understanding The Results
- Staging Cirrhosis
- Is There A Natural Way To Improve Liver Fibrosis?